Fondaparinux
(KANJSNBRCNMZMV-ABRZTLGGSA-N)
Structure
- SMILES
- CO[C@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@@H]([C@H]1NS(=O)(=O)O)O)O[C@@H]1O[C@@H](C(=O)O)[C@H]([C@@H]([C@H]1OS(=O)(=O)O)O)O[C@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@@H]([C@H]1NS(=O)(=O)O)OS(=O)(=O)O)O[C@@H]1O[C@H](C(=O)O)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@@H]([C@H]1NS(=O)(=O)O)O)O
- Type(s)
- Approved; Investigational
- ATC code(s)
- B01AX05
- Molecular Formula:
- C31H53N3O49S8
- Molecular Weight:
- 1508.260
- Log P:
- -3.9310
- Hydrogen Bond Acceptor:
- 52
- Hydrogen Bond Donor:
- 19
- TPSA:
- 872.52
- CAS Number(s):
- 104993-28-4
Synonym(s)
1.
Fondaparinux
2.
Arixtra
3.
Fondaparinux Sodium
4.
Quixidar
External Link(s)
| MeSH | D000077425 |
| PubChem Compound | 5282448 49852292 |
| ChEBI | 61033 |
| CHEMBL | CHEMBL1201202 |
| DrugBank | DB00569 |
| DrugCentral | 1236 |
| IUPHAR/BPS Guide to PHARMACOLOGY | 6819 |
Adverse Drug Event(s)
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.